

Marin Veldic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6057357/publications.pdf>

Version: 2024-02-01

73
papers

3,643
citations

185998

28
h-index

133063

59
g-index

79
all docs

79
docs citations

79
times ranked

3845
citing authors

#	ARTICLE	IF	CITATIONS
1	Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis. <i>Journal of Affective Disorders</i> , 2022, 302, 385-400.	2.0	54
2	The role of base excision repair in major depressive disorder and bipolar disorder. <i>Journal of Affective Disorders</i> , 2022, 306, 288-300.	2.0	4
3	Clinical and Genetic Correlates of Bipolar Disorder With Childhood-Onset Attention Deficit Disorder. <i>Frontiers in Psychiatry</i> , 2022, 13, 884217.	1.3	3
4	Clinical Phenotype of Tardive Dyskinesia in Bipolar Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2022, 42, 159-162.	0.7	1
5	Differences in perceived life stress in bipolar I and II disorder: Implications for future epigenetic quantification. <i>Personalized Medicine in Psychiatry</i> , 2022, 33-34, 100093.	0.1	0
6	Quantification of diet quality utilizing the rapid eating assessment for participants-shortened version in bipolar disorder: Implications for prospective depression and cardiometabolic studies. <i>Journal of Affective Disorders</i> , 2022, 310, 150-155.	2.0	5
7	The genetics of bipolar disorder with obesity and type 2 diabetes. <i>Journal of Affective Disorders</i> , 2022, 313, 222-231.	2.0	6
8	Symptoms of bipolar disorder are associated with lower bariatric surgery completion rates and higher food addiction. <i>Eating Behaviors</i> , 2021, 40, 101462.	1.1	8
9	Long-term lithium therapy and risk of chronic kidney disease in bipolar disorder: A historical cohort study. <i>Bipolar Disorders</i> , 2021, 23, 715-723.	1.1	19
10	Body mass index and blood pressure in bipolar patients: Target cardiometabolic markers for clinical practice. <i>Journal of Affective Disorders</i> , 2021, 282, 637-643.	2.0	7
11	Characterisation of age and polarity at onset in bipolar disorder. <i>British Journal of Psychiatry</i> , 2021, 219, 659-669.	1.7	20
12	Association of Optimal Lamotrigine Serum Levels and Therapeutic Efficacy in Mood Disorders. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 681-686.	0.7	6
13	Effect of neuropsychiatric medications on mitochondrial function: For better or for worse. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 127, 555-571.	2.9	15
14	Gene expression of methylation cycle and related genes in lymphocytes and brain of patients with schizophrenia and non-psychotic controls. <i>Biomarkers in Neuropsychiatry</i> , 2021, 5, 100038.	0.7	7
15	Revisiting the bipolar disorder with migraine phenotype: Clinical features and comorbidity. <i>Journal of Affective Disorders</i> , 2021, 295, 156-162.	2.0	3
16	Plasma Cell-Free DNA Methylomics of Bipolar Disorder With and Without Rapid Cycling. <i>Frontiers in Neuroscience</i> , 2021, 15, 774037.	1.4	4
17	Type 1 equilibrative nucleoside transporter (ENT1) regulates sex-specific ethanol drinking during disruption of circadian rhythms. <i>Addiction Biology</i> , 2020, 25, e12801.	1.4	13
18	Efficacy and tolerability of adjunctive modafinil/armodafinil in bipolar depression: A meta-analysis of randomized controlled trials. <i>Bipolar Disorders</i> , 2020, 22, 109-120.	1.1	17

#	ARTICLE	IF	CITATIONS
19	Differential Dorsolateral Prefrontal Cortex Proteomic Profiles of Suicide Victims with Mood Disorders. <i>Genes</i> , 2020, 11, 256.	1.0	9
20	Alterations in levels of 8-Oxo-2'-deoxyguanosine and 8-Oxoguanine DNA glycosylase 1 during a current episode and after remission in unipolar and bipolar depression. <i>Psychoneuroendocrinology</i> , 2020, 114, 104600.	1.3	25
21	The Relationship between DNA Methylation and Antidepressant Medications: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2020, 21, 826.	1.8	47
22	Label-free proteomics differences in the dorsolateral prefrontal cortex between bipolar disorder patients with and without psychosis. <i>Journal of Affective Disorders</i> , 2020, 270, 165-173.	2.0	6
23	Dissecting the Epigenetic Changes Induced by Non-Antipsychotic Mood Stabilizers on Schizophrenia and Affective Disorders: A Systematic Review. <i>Frontiers in Pharmacology</i> , 2020, 11, 467.	1.6	12
24	Methylation of Brain Derived Neurotrophic Factor (BDNF) Val66Met CpG site is associated with early onset bipolar disorder. <i>Journal of Affective Disorders</i> , 2020, 267, 96-102.	2.0	13
25	Potential pharmacogenomic targets in bipolar disorder: considerations for current testing and the development of decision support tools to individualize treatment selection. <i>International Journal of Bipolar Disorders</i> , 2020, 8, 23.	0.8	8
26	Genome-wide DNA methylomic differences between dorsolateral prefrontal and temporal pole cortices of bipolar disorder. <i>Journal of Psychiatric Research</i> , 2019, 117, 45-54.	1.5	24
27	EAAT2 as a Research Target in Bipolar Disorder and Unipolar Depression: A Systematic Review. <i>Molecular Neuropsychiatry</i> , 2019, 5, 44-59.	3.0	20
28	Increased plasma levels of 8-oxoguanine DNA glycosylase-1 in bipolar disorder. <i>Psychiatry and Clinical Neurosciences</i> , 2019, 73, 719-720.	1.0	5
29	Association of Cytomegalovirus and <i>Toxoplasma gondii</i> Antibody Titers With Bipolar Disorder. <i>JAMA Psychiatry</i> , 2019, 76, 1285.	6.0	36
30	Genetic variant in SLC1A2 is associated with elevated anterior cingulate cortex glutamate and lifetime history of rapid cycling. <i>Translational Psychiatry</i> , 2019, 9, 149.	2.4	19
31	Chronic caffeine exposure in adolescence promotes diurnal, biphasic mood-cycling and enhanced motivation for reward in adult mice. <i>Behavioural Brain Research</i> , 2019, 370, 111943.	1.2	6
32	Cytochrome P450 2C19 Poor Metabolizer Phenotype in Treatment Resistant Depression: Treatment and Diagnostic Implications. <i>Frontiers in Pharmacology</i> , 2019, 10, 83.	1.6	12
33	A Review of Epigenetics of PTSD in Comorbid Psychiatric Conditions. <i>Genes</i> , 2019, 10, 140.	1.0	36
34	Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure. <i>Journal of Affective Disorders</i> , 2019, 246, 62-68.	2.0	16
35	Association of schizophrenia polygenic risk score with manic and depressive psychosis in bipolar disorder. <i>Translational Psychiatry</i> , 2018, 8, 188.	2.4	44
36	450. In Bipolar Disorder, SLC1A2 Promoter Hypomethylation is Associated with Binge Eating Disorder and Nicotine Dependence. <i>Biological Psychiatry</i> , 2017, 81, S183-S184.	0.7	1

#	ARTICLE	IF	CITATIONS
37	Exploring hepsin functional genetic variation association with disease specific protein expression in bipolar disorder: Applications of a proteomic informed genomic approach. <i>Journal of Psychiatric Research</i> , 2017, 95, 208-212.	1.5	4
38	Metabotropic glutamate receptors as emerging research targets in bipolar disorder. <i>Psychiatry Research</i> , 2017, 257, 327-337.	1.7	35
39	A genome wide association study suggests the association of muskelin with early onset bipolar disorder: Implications for a GABAergic epileptogenic neurogenesis model. <i>Journal of Affective Disorders</i> , 2017, 208, 120-129.	2.0	17
40	Differential SLC1A2 Promoter Methylation in Bipolar Disorder With or Without Addiction. <i>Frontiers in Cellular Neuroscience</i> , 2017, 11, 217.	1.8	26
41	Genetic Risk Score Analysis in Early-Onset Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 1337-1343.	1.1	21
42	Clinical features of bipolar spectrum with binge eating behaviour. <i>Journal of Affective Disorders</i> , 2016, 201, 95-98.	2.0	29
43	Prevalence and correlates of DSM-5 eating disorders in patients with bipolar disorder. <i>Journal of Affective Disorders</i> , 2016, 191, 216-221.	2.0	62
44	Association of brain-derived neurotrophic factor (BDNF) Val66Met polymorphism with early-onset bipolar disorder. <i>Bipolar Disorders</i> , 2015, 17, 645-652.	1.1	20
45	Development of a bipolar disorder biobank: differential phenotyping for subsequent biomarker analyses. <i>International Journal of Bipolar Disorders</i> , 2015, 3, 30.	0.8	55
46	Feasibility of investigating differential proteomic expression in depression: implications for biomarker development in mood disorders. <i>Translational Psychiatry</i> , 2015, 5, e689-e689.	2.4	60
47	CLUMSY VEIN, the Arabidopsis DEAH Prp16 ortholog, is required for auxin-mediated development. <i>Plant Journal</i> , 2015, 81, 183-197.	2.8	24
48	Clinical Risk Factors and Serotonin Transporter Gene Variants Associated With Antidepressant-Induced Mania. <i>Journal of Clinical Psychiatry</i> , 2015, 76, 174-180.	1.1	27
49	Current landscape, unmet needs, and future directions for treatment of bipolar depression. <i>Journal of Affective Disorders</i> , 2014, 169, S17-S23.	2.0	29
50	DNA Methylation/Demethylation Network Expression in Psychotic Patients with a History of Alcohol Abuse. <i>Alcoholism: Clinical and Experimental Research</i> , 2013, 37, 417-424.	1.4	31
51	Pharmacogenomics of antidepressant induced mania: A review and meta-analysis of the serotonin transporter gene (5HTTLPR) association. <i>Journal of Affective Disorders</i> , 2012, 136, e21-e29.	2.0	36
52	A neurochemical basis for an epigenetic vision of psychiatric disorders (1994-2009). <i>Pharmacological Research</i> , 2011, 64, 344-349.	3.1	14
53	L-methionine decreases dendritic spine density in mouse frontal cortex. <i>NeuroReport</i> , 2010, 21, 543-548.	0.6	16
54	An upregulation of DNA-methyltransferase 1 and 3a expressed in telencephalic GABAergic neurons of schizophrenia patients is also detected in peripheral blood lymphocytes. <i>Schizophrenia Research</i> , 2009, 111, 115-122.	1.1	117

#	ARTICLE	IF	CITATIONS
55	GABAergic promoter hypermethylation as a model to study the neurochemistry of schizophrenia vulnerability. <i>Expert Review of Neurotherapeutics</i> , 2009, 9, 87-98.	1.4	60
56	Reelin Downregulation as a Prospective Treatment Target for GABAergic Dysfunction in Schizophrenia. , 2008, , 341-363.		1
57	Reviewing the Role of DNA (Cytosine-5) Methyltransferase Overexpression in the Cortical GABAergic Dysfunction Associated with Psychosis Vulnerability. <i>Epigenetics</i> , 2007, 2, 29-36.	1.3	86
58	Down-regulation of neurosteroid biosynthesis in corticolimbic circuits mediates social isolation-induced behavior in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 18736-18741.	3.3	160
59	S-adenosyl methionine and DNA methyltransferase-1 mRNA overexpression in psychosis. <i>NeuroReport</i> , 2007, 18, 57-60.	0.6	89
60	Epigenetic mechanisms expressed in basal ganglia GABAergic neurons differentiate schizophrenia from bipolar disorder. <i>Schizophrenia Research</i> , 2007, 91, 51-61.	1.1	137
61	Selective epigenetic alteration of layer I GABAergic neurons isolated from prefrontal cortex of schizophrenia patients using laser-assisted microdissection. <i>Molecular Psychiatry</i> , 2007, 12, 385-397.	4.1	173
62	From The Cover: The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 1587-1592.	3.3	210
63	Epigenetic Targets in GABAergic Neurons to Treat Schizophrenia. <i>Advances in Pharmacology</i> , 2006, 54, 95-117.	1.2	23
64	Characterization of brain neurons that express enzymes mediating neurosteroid biosynthesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 14602-14607.	3.3	335
65	GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon. <i>Psychopharmacology</i> , 2005, 180, 191-205.	1.5	237
66	DNA methyltransferase 1 regulates reelin mRNA expression in mouse primary cortical cultures. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 1749-1754.	3.3	124
67	In psychosis, cortical interneurons overexpress DNA-methyltransferase 1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 2152-2157.	3.3	249
68	Should allosteric positive modulators of GABAA receptors be tested in the treatment of schizophrenia?. <i>Schizophrenia Research</i> , 2005, 73, 367-368.	1.1	7
69	Neurochemical Basis for an Epigenetic Vision of Synaptic Organization. <i>International Review of Neurobiology</i> , 2004, 59, 73-91.	0.9	8
70	DNA-methyltransferase 1 mRNA is selectively overexpressed in telencephalic GABAergic interneurons of schizophrenia brains. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 348-353.	3.3	285
71	Neurosciences in the Third Millennium: A Tribute to Mimo Costa. <i>Critical Reviews in Neurobiology</i> , 2004, 16, v.	3.3	106
72	GABAergic Cortical Neuron Chromatin as a Putative Target to Treat Schizophrenia Vulnerability. <i>Critical Reviews in Neurobiology</i> , 2003, 15, 121-142.	3.3	45

#	ARTICLE	IF	CITATIONS
73	REELIN and Schizophrenia:: A Disease at the Interface of the Genome and the Epigenome. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2002, 2, 47-57.	3.4	146